Amy Bachrodt, SVP of Finance at Maze Therapeutics, Inc. ($MAZE), sold shares on the open market eleven times in the last 365 days, totaling about $1.5 million. Her most recent sale occurred on March 2, 2026. These sales rank 4,076th among 11,678 insiders in the database by total value sold, compared to an average of $8.6 million per insider and 6.4 transactions. Bachrodt made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 300 | $30.34 | 12,965.0000 | 48,119,444 | 2.26% | 0.00% |
| April 1, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 2200 | $29.32 | 13,265.0000 | 48,119,444 | 14.23% | 0.00% |
| April 1, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 2500 | $10.42 | 15,465.0000 | 48,119,444 | 19.28% | 0.01% |
| April 1, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 2500 | $0.00 | 33,833.0000 | 48,119,444 | 6.88% | 0.01% |
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 3700 | $45.47 | 12,965.0000 | 48,119,444 | 22.20% | 0.01% |
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 5000 | $10.42 | 17,965.0000 | 48,119,444 | 38.57% | 0.01% |
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 1300 | $44.44 | 16,665.0000 | 48,119,444 | 7.24% | 0.00% |
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | A | Restricted Stock Units | 16000 | $0.00 | 16,000.0000 | 48,119,444 | 9999.99% | 0.03% |
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | A | Stock Option (Right to Buy) | 32000 | $0.00 | 32,000.0000 | 48,119,444 | 9999.99% | 0.07% |
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 5000 | $0.00 | 36,333.0000 | 48,119,444 | 12.10% | 0.01% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 156 | $10.42 | 17,965.0000 | 48,119,444 | 0.88% | 0.00% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 156 | $0.00 | 41,333.0000 | 48,119,444 | 0.38% | 0.00% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 4844 | $0.00 | 3,025.0000 | 48,119,444 | 61.56% | 0.01% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 736 | $46.63 | 12,965.0000 | 48,119,444 | 5.37% | 0.00% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 4064 | $46.03 | 13,701.0000 | 48,119,444 | 22.88% | 0.01% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 200 | $44.15 | 17,765.0000 | 48,119,444 | 1.11% | 0.00% |
| Feb. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 4844 | $10.42 | 17,809.0000 | 48,119,444 | 37.36% | 0.01% |
| Jan. 22, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 5000 | $45.52 | 12,965.0000 | 48,119,444 | 27.83% | 0.01% |
| Jan. 22, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 2497 | $10.42 | 15,462.0000 | 48,119,444 | 19.26% | 0.01% |
| Jan. 22, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 2503 | $10.42 | 17,965.0000 | 48,119,444 | 16.19% | 0.01% |
| Jan. 22, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 2497 | $0.00 | 486.0000 | 48,119,444 | 83.71% | 0.01% |
| Jan. 22, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 2503 | $0.00 | 7,869.0000 | 48,119,444 | 24.13% | 0.01% |
| Jan. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 2405 | $38.70 | 15,560.0000 | 48,119,444 | 13.39% | 0.00% |
| Jan. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 4796 | $10.42 | 17,965.0000 | 48,119,444 | 36.42% | 0.01% |
| Jan. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 204 | $10.42 | 13,169.0000 | 48,119,444 | 1.57% | 0.00% |
| Jan. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 4796 | $0.00 | 2,983.0000 | 48,119,444 | 61.65% | 0.01% |
| Jan. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 204 | $0.00 | 2,377.0000 | 48,119,444 | 7.90% | 0.00% |
| Jan. 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 2595 | $39.57 | 12,965.0000 | 48,119,444 | 16.68% | 0.01% |
| Dec. 30, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 2605 | $10.42 | 17,965.0000 | 48,119,444 | 16.96% | 0.01% |
| Dec. 30, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 2395 | $10.42 | 15,360.0000 | 48,119,444 | 18.47% | 0.00% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 600 | $41.16 | 12,965.0000 | 48,119,444 | 4.42% | 0.00% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 9400 | $40.54 | 13,565.0000 | 48,119,444 | 40.93% | 0.02% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 9876 | $10.42 | 22,965.0000 | 48,119,444 | 75.45% | 0.02% |
| Dec. 30, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 2605 | $0.00 | 2,581.0000 | 48,119,444 | 50.23% | 0.01% |
| Dec. 30, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 2395 | $0.00 | 1.0000 | 48,119,444 | 99.96% | 0.00% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 9876 | $0.00 | 23,834.0000 | 48,119,444 | 29.30% | 0.02% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Stock Option (Right to Buy) | 124 | $0.00 | 2,396.0000 | 48,119,444 | 4.92% | 0.00% |
| Dec. 30, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | S | Common Stock | 5000 | $40.08 | 12,965.0000 | 48,119,444 | 27.83% | 0.01% |
| Dec. 29, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | M | Common Stock | 124 | $10.42 | 13,089.0000 | 48,119,444 | 0.96% | 0.00% |
| Sept. 22, 2025 | Maze Therapeutics, Inc. | $MAZE | Bachrodt Amy | SVP, Finance | A | Restricted Stock Units | 22000 | $0.00 | 22,000.0000 | 0 | 9999.99% | 0.00% |